Dosimetric predictors of diarrhea during radiotherapy for prostate cancer
暂无分享,去创建一个
[1] F. Sedlmayer,et al. A strategy for the use of image-guided radiotherapy (IGRT) on linear accelerators and its impact on treatment margins for prostate cancer patients , 2008, Strahlentherapie und Onkologie.
[2] C. Vanhove,et al. Longitudinal Assessment of Parotid Function in Patients Receiving Tomotherapy for Head-and-Neck Cancer , 2008, Strahlentherapie und Onkologie.
[3] M. Sormani,et al. Comparison of three strategies to delineate the bowel for whole pelvis IMRT of prostate cancer. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[4] D. Yan,et al. The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer. , 2008, International journal of radiation oncology, biology, physics.
[5] G. Sanguineti,et al. Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer , 2008, Acta oncologica.
[6] J. Lechner,et al. Optimized Conformal Paraaortic Lymph Node Irradiation is not Associated with Enhanced Renal Toxicity , 2007, Strahlentherapie und Onkologie.
[7] L. Constine,et al. Normal tissue tolerance dose metrics for radiation therapy of major organs. , 2007, Seminars in radiation oncology.
[8] J. Debus,et al. Local High-Dose Radiotherapy and Sparing of Normal Tissue Using Intensity-Modulated Radiotherapy (IMRT) for Mucosal Melanoma of the Nasal Cavity and Paranasal Sinuses , 2007, Strahlentherapie und Onkologie.
[9] L. Tho,et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. , 2006, International journal of radiation oncology, biology, physics.
[10] W. Tomé,et al. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy. , 2005, Acta oncologica.
[11] G. Sanguineti,et al. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer? , 2006, International journal of radiation oncology, biology, physics.
[12] Di Yan,et al. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity. , 2005, International journal of radiation oncology, biology, physics.
[13] G. Sanguineti,et al. IMRT to Escalate the Dose to the Prostate while Treating the Pelvic Nodes , 2005, Strahlentherapie und Onkologie.
[14] Y. Kvinnsland,et al. Testing the new ICRU 62 'Planning Organ at Risk Volume' concept for the rectum. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[15] John C Roeske,et al. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[16] G. Sanguineti,et al. 890 Acute small bowel and colon toxicity after pelvic IMRT for prostate cancer , 2003 .
[17] G. Boeckxstaens,et al. A prospective evaluation of anorectal function after total mesorectal excision in patients with a rectal carcinoma. , 2003, Surgery.
[18] Michael J. Zelefsky,et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. , 2002, International journal of radiation oncology, biology, physics.
[19] Claudio Fiorino,et al. Rectum contouring variability in patients treated for prostate cancer: impact on rectum dose-volume histograms and normal tissue complication probability. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[20] Marcel van Herk,et al. Margins for geometric uncertainty around organs at risk in radiotherapy. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[21] T. Fleming,et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Jenrette,et al. Stereotactic radiosurgery treatment dose planning by optimizing the collimator sizes and the 3-D coordinates of the isocenter(s) , 1994 .
[23] P. Carroll,et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.
[24] B Pickett,et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.
[25] M. Goitein,et al. Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.